GuidePath evaluated the imaging efficacy of [18F]CTT1057 PET for the detection of PSMA-positive prostate cancer lesions in a patient population enrolled predominantly at first BCR, after RP, with low PSA levels. Here, FOLH1 is linked to prostate carcinoma.